



ORIGINAL ARTICLE

Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany

Tammo L. Tergast¹ | Sarah Blach² | Frank Tacke³ | Thomas Berg⁴ | Markus Cornberg^{1,5}  | Achim Kautz⁶ | Michael Manns^{1,5} | Homie Razavi² | Christoph Sarrazin^{7,8} | Yvonne Serfert⁵  | Ingo van Thiel⁹ | Stefan Zeuzem¹⁰ | Heiner Wedemeyer^{1,5}

¹Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

²CDA Foundation, Lafayette, Colorado, USA

³Department of Hepatology & Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany

⁴Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany

⁵Leberstiftungs-GmbH Deutschland, Hannover, Germany

⁶Kautz5 gUG, Köln, Germany

⁷Department of Internal Medicine and Liver Center, St. Josefs-Hospital Wiesbaden, Wiesbaden, Germany

⁸Viral Hepatitis Research Group, Goethe-University Hospital Frankfurt, Frankfurt, Germany

⁹Deutsche Leberhilfe, Köln, Germany

¹⁰Department of Medicine, University Hospital, Frankfurt, Germany

Correspondence

Heiner Wedemeyer, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany.
Email: Wedemeyer.Heiner@mh-hannover.de

Funding information

The funding for this project was provided by Gilead Sciences. The funders had no role in the study design, data collection, analysis, interpretation of data or preparation of the manuscript

Abstract

In 2014, an analysis was conducted to evaluate the hepatitis C virus (HCV) epidemiology and disease burden in Germany. Since then, there have been considerable developments in HCV management such as the implementation of direct acting antivirals. The aim of this analysis was to assess the recent data available for Germany, establish an updated 2020 HCV prevalence and cascade of care and evaluate the impact of what-if scenarios on the future burden of disease using modelling analysis. A dynamic Markov model was used to forecast the HCV disease burden in Germany. Model inputs were retrieved through literature review, unpublished sources and expert input. Next, three “what-if” scenarios were developed to evaluate the status quo, COVID-19 pandemic, and steps needed to achieve the WHO targets for elimination. At the beginning of 2020, there were 189,000 (95% UI: 76,700–295,000) viremic infections in Germany, a decline of more than 85,000 viremic infections since 2012. Annual treatment starts went down since 2015. Compared with 2019, the COVID-19 pandemic resulted in a further 11% decline in 2020. If this continues for two years, it could result in 110 excess HCC cases and 200 excess liver related deaths by 2030. To achieve the

Abbreviations: COVID-19, coronavirus disease 2019; DEGS 1, German health interview and examination survey for adults; HCC, hepatitis C virus; RKI, hepatocellular carcinoma; HCV, Robert Koch Institute; SVR, sustained virologic response; UI, uncertainty interval; WHO, World Health Organization.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Journal of Viral Hepatitis* published by John Wiley & Sons Ltd.

WHO targets, 81,200 people need to be diagnosed, with 118,600 initiated on treatment by 2030. This could also avert 1,020 deaths and 720 HCC cases between 2021 and 2030. Germany has made strides towards HCV elimination, but more efforts are needed to achieve the WHO targets by 2030.

KEYWORDS

COVID-19, elimination, Germany, hepatitis C virus

1 | INTRODUCTION

In 2014, an analysis was conducted to evaluate the hepatitis C virus (HCV) epidemiology and disease burden in Germany.¹ Since that time, the epidemiology of HCV has changed rapidly due to the vast implementation of direct acting antiviral (DAA) therapies since 2014 with high rates (>90%) of sustained virological response (SVR). Germany made advancements towards HCV elimination and was one of the first countries to provide universal access to the new therapies with no restrictions on the basis of fibrosis. Between 2014 and 2019, almost 90,000 patients were initiated on therapies,² accounting for approximately 34% of the 267,000 viremic infections estimated at the end of 2013.³ However, the rates of screening and diagnosis have lagged, with fewer than 32,000 infections notified to the Robert Koch Institute (RKI) in the same time frame.⁴ In Germany, clinicians and laboratories have to report viremic HCV infection to the patients' local health department. Population-based screening programmes did not exist until October 2021 and national guidelines only recommend to screen high-risk groups such as people who inject drugs (PWID) or patients on haemodialysis.⁵

In 2020, the coronavirus disease 2019 (COVID-19) pandemic posed a new challenge for HCV elimination efforts. Some countries report a drastic decrease of overall hepatological activity and HCV-screenings in ambulatory clinics and emergency departments.⁶ As of 14 September 2021, over 4.1 million total COVID-19 infections in Germany were reported to RKI, and more than 55.4 million vaccine doses were administered (>66% of the population vaccinated).^{4,7} The number of HCV infections reported to RKI dropped more than 20%, from 5953 in 2019 to 4559 in 2020, potentially as a result of health service disruptions.⁴ Compared with the same time frame in 2019, the first 22 weeks of 2021 showed an even greater (25%) decline in HCV notifications.⁴

In the seven years that have passed since our original analysis, there have been considerable developments in HCV management such as high treatment availability and efficacy.⁸⁻¹⁰ The objective of this analysis was to assess the recent data available for Germany and establish an updated 2020 baseline for the HCV prevalence and cascade of care, and then to evaluate the impact of what-if scenarios on the future burden of HCV disease in Germany using modelling analysis.

2 | MATERIAL AND METHODS

The data used for modelling were obtained through literature review, unpublished sources and expert input. Next, a dynamic Markov model was used. HCV prevalence,^{11,12} prevalence by age and sex,^{11,12} the number of persons newly diagnosed⁴ and previously diagnosed¹³ and the number initiated on the treatment² were used to seed and calibrate the model. Inputs parameters are included in Table 1. Many of these inputs have been described in detail previously, with newer inputs described briefly in the Supporting information Appendix.¹⁴

The number of true new (acute) infections is not systematically captured and estimates of acute infections are likely to be under-reported. As a result, new infections were back-calculated in the model using known prevalence and considering trends in transmission risk factors over time (see Appendix in Supporting information). After the last year of data, the model calculated future incidence as a function of prevalence as has been described previously. In addition, the annual number of new viremic infections entering Germany via migration was calculated for 2019 considering net immigration data by country of origin,¹⁵ country- and sex-specific anti-HCV prevalence among migrants¹⁶ and viremic rate among refugees.¹⁷

TABLE 1 Model inputs and sources

Input	Year	Estimate	Source
Viremic prevalence	2012	274,700 (165,000–494,400)	Expert input ¹⁴
Prevalence by age and sex	2012	20% DEGS; 80% RKI (see Appendix in Supporting information)	11,12
Previously diagnosed	2012	48%	13
Annual newly diagnosed (HCV-RNA+)	2019	5,940	4
Annual number treated	2019	9,700	Prescription sales data
	2020	7,600	
Annual new viremic infections associated with migration	2019	2,870	15,16




FIGURE 1 Waterfall chart indicating the number of viremic infections from 2012 to 2020, including the number of incident infections, treated/cured and deaths




FIGURE 2 Cascade of care in 2020

3.2 | COVID-19 scenario

Empirical data collected at the beginning of 2021 found that in actuality, only 7,600 patients were initiated on treatment in 2020 due to the COVID-19 pandemic, an 11% decline relative to the previously forecast treatment estimate for 2020 (Appendix 8 in Supporting information). Two years of partial disruption to treatment (7600 treated per year) (Table 2) would result in nearly 110 excess HCC and 200 excess liver-related deaths through 2030.

3.3 | Elimination scenario

Achieving all of the WHO targets by 2030 would require an increased effort to screen and diagnose new infections, with 81,200 newly diagnosed and 118,600 patients initiated on treatment needed between 2021 and 2030 (Table 2 + Appendix 8 in

Supporting information). Under this scenario, Germany would not only achieve the targets for elimination as defined by WHO but also would avert 1020 deaths and 720 HCC cases between 2021 and 2030, relative to the 2019 base case scenario (Figure 3). By 2030, there would be only 81,900 viremic infections remaining, a prevalence of 0.10%.

3.4 | Uncertainty analysis and model validation

The inputs which contributed to the greatest uncertainty in the 2020 viremic prevalence included basic model parameters (transition probabilities within the natural course of infection) as well as the input for anti-HCV prevalence in 2012 (Appendix 1-4 in Supporting information). Together, base 2012 prevalence and the rate of spontaneous clearance accounted for >96% of uncertainty around total infections in 2020.




FIGURE 3 Progress toward the WHO 2030 targets for liver-related deaths and incidence of HCV under the Base 2019 and WHO targets scenarios, 2015–2030. Based on the assumptions provided in Table 1

In addition, uncertainty around the number of HCV infections estimated to enter Germany through migration was calculated. In 2019, around 5025 (95% UI: 4450–5610) anti-HCV+ infections were estimated to enter Germany through migration, although prevalence estimates, as well as the viremic rate, were based on studies of refugees. Using these sources, applied to the number of net immigrants in 2019, more than 50% of HCV infections among migrants would have been from countries listed as “other”, with 16% from Russia (Appendix 5 in Supporting information).

Empirical data and expert input suggested between 390 and 1100 HCV-related HCC cases occur annually in Germany (Appendix 6 in Supporting information). In 2018, in the model forecast, there would be around 710 incident HCC cases among HCV-RNA+ persons.

4 | DISCUSSION

In its strategy to eliminate hepatitis B, C and D, the WHO has defined indicators to monitor the progress. However, these indicators are not systematically captured in Germany, making it challenging to assess whether the country is or is not “on track” for HCV elimination by 2030.²² A 2019 analysis indicated that Germany would be on track to reach the WHO goals by 2030, assuming a minimum of 9900 patients would be initiated on treatment per year.²³ However, our data collection efforts demonstrated that in spite of a rapid initial

response to the HCV epidemic in Germany, the number of patients treated annually dipped below the treatment threshold in 2019 (only 9700 patients initiated on treatment). Our baseline assumptions of continued treatment declines would mean Germany is no longer on track to achieve the WHO goals by 2030. Treatment declines seen in 2020 from the first year of the COVID-19 pandemic (7600 patients treated) additionally support that Germany is getting further from achieving the goals than it was in previous years. This may result in more late-presenting patients with advanced stages of liver disease. The present data indicate over 1000 additional liver-related deaths and over 700 additional cases of HCC until 2030, if the observed trend continuous. Under these assumptions, the WHO elimination goal will be delayed by approximately eight years. Importantly, diagnosis, therapy and monitoring of patients with HCV were impaired during the COVID-19 pandemic, even though the majority of centres do not see healthcare problems in the medium and long term.²⁴ To what extent the COVID-19 pandemic will impact the amount of liver-related deaths or HCC cases in the future will have to be determined in the next years. Yet, avoiding excess morbidity and mortality will need dedicated programmes.

Germany lacks an active wide-scale national screening strategy and is currently running out of patients to treat. Family physicians offer a check-up at age 35 to every adult that includes testing for anti-HCV since October 2021. Moreover, primary care physicians are allowed to prescribe DAA therapies. Thus, it is tempting to speculate that a large-scale-up in screening and treatment could occur

within the next years. Unfortunately, only about half of the population attends such a screening. Furthermore, one study indicates that people with lower socio-economic status and therefore potential high-risk groups are less likely to participate in this check-up.²⁵ However, to achieve the elimination targets, more patients need to be screened and diagnosed. In 2020, the United States expanded this effort by endorsing a one-time-screening of all adults over 18 years of age, alongside routine screening of pregnant women.²⁶ This was found to be a cost-effective strategy in any population with a prevalence of $\geq 0.1\%$.^{26,27} In Egypt, a country with a historically high prevalence of HCV, a large-scale population-based active screening and treatment campaign resulted in a drastic decrease of HCV burden in the whole country.²⁸ This, however, was only possible due to political will and dedicated funding. As of now large-scale population based one-time screening that includes the younger population, seems to be the most effective way to eliminate HCV.

Targeting priority populations is a cornerstone to reach the WHO HCV elimination goal and intravenous drug use is the most frequent known mode of acquisition of HCV infection in Germany.²⁹ Risk for HCV infection is over 200 times higher compared with the general population. Between 2011 and 2015, a study of PWID revealed an HCV prevalence of 23%–54%.³⁰ The same study reported that only 13%–43% of all individuals with a treatment indication ever received antiviral therapy that led to SVR. Unfortunately, annual serosurveys are not available in this priority population and there are no data on the impact of DAA on HCV prevalence in this group. DAA therapy is well tolerated; so, treatment uptake may have increased.³¹ A new pilot study is on the way suggest change to establish a surveillance system for blood borne viruses and sexually transmitted infections in PWID.³² Furthermore, care could be facilitated through micro-elimination attempts. In Germany, opioid substitution therapy and NSP programmes are already available and could further be enhanced with the addition of point of care HCV testing.³³

The true impact of migration on the HCV prevalence and disease burden in Germany is quite uncertain. First, most studies focus on refugees or asylum seekers, rather than the general immigrant population, which may result in a higher estimated prevalence. Second, as HCV treatment becomes more common even in developing countries, the number of persons migrating who are still HCV-RNA+ is expected to decline. Nonetheless, screening of migrants, especially from high-endemic regions such as sub-Saharan Africa or Eastern Europe, may be a useful strategy to identify infections and link patients to care.³⁴

There are some limitations that should be considered when interpreting our study results, the first being the availability of nationally representative data. The prevalence of HCV in Germany is expected to be low, but a nationally representative random sample serosurvey for HCV has not been conducted since 2012. Although this type of survey is the gold standard, previous efforts have found that even well-conducted serosurveys may miss key populations for HCV (e.g., DEGS 1 study which identified no HCV infections in persons under the age of 40 years). This is particularly relevant for vulnerable groups at risk of (yet unidentified) HCV infections. To improve

the data quality in Germany in the future, the RKI is working closely with the European Centre for Disease Prevention and Control, and technical study protocols to conduct HCV-serosurveys for European Union countries have already been established.³⁵

Similarly, the estimate of percent of cases diagnosed was retrieved through a study of patients >35years of age who attended “check-up” visits (20%–25% of the population with a significant selection bias). The proportion of individuals aware of their infection is likely lower in younger age groups. To account for the limitations of an individual study, weighted estimates and/or ranges were employed as appropriate. In addition, the model outcomes were validated against empirical data around liver cancers in Germany. The model is calibrated to prevalence data (and prevalence by age and sex), with end-stage outcomes calculated according to the standard disease-specific progression rates. Without modifying these progression rates and considering the base model inputs described in this paper, the model was able to predict a reasonable number of HCC cases in Germany, providing further support for inputs selected.

To conclude, Germany has made strides towards HCV elimination, but more efforts are needed to achieve the WHO targets by 2030. Specifically, case finding to link previously diagnosed patients to care as well as screening coupled with timely treatment will be necessary to diagnose and treat an average of 8000 and 12000 infections per year respectively. These targets are feasible given previous numbers of patients diagnosed and treated; however, increased efforts and resources will be required to reach these remaining patients as the prevalence in the country declines.

ACKNOWLEDGEMENTS

The authors would like to acknowledge Dr. Matthias an der Heiden and Dr. Ruth Zimmerman from the Robert Koch Institute for their substantial contributions to data collection, analysis and interpretation throughout the course of this project. Open Access funding enabled and organized by Projekt DEAL.

CONFLICTS OF INTEREST

T.L.T. has nothing to disclose. S.B. is an employee of the Center for Disease Analysis Foundation (CDAF). Over the past 3 years, CDAF has received research funding from Gilead, AbbVie and Vaccine Impact Modeling Consortium. CDAF has also received grants from CDC Foundation, John Martin Foundation, ASTHO, Zeshan Foundation and private donors. F.T.'s laboratory has received funding from Gilead, BMS, Inventiva and Allergan. A.K. has nothing to disclose. H.R. has been a member of advisory boards for Gilead, AbbVie, Merck and VBI Vaccines. All proceeds are donated to CDAF. He is the managing director of Center for Disease Analysis (CDA) and CDAF. Y.S. has nothing to disclose. S.Z. has been a consultant and speaker for Abbvie, Gilead, Intercept, Janssen, Merck/MSD, Novo Nordisk and Sobi.

ORCID

Markus Cornberg  <https://orcid.org/0000-0002-9141-8001>

Yvonne Serfert  <https://orcid.org/0000-0002-6263-0230>

REFERENCES

1. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. *J Viral Hepat.* 2014;21(Suppl 1):60-89.
2. Robert Koch Institute. *Epidemiological Bulletin* 30/31 2020. [Viral Hepatitis B and D as Well as Viral Hepatitis C in 2019]. 23/7/2020 2020.
3. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat.* 2014;21(Suppl 1):34-59.
4. SurvStat@RKI 2.0 2020. 2020. <https://survstat.rki.de>. Accessed 1 October 2020.
5. Sarrazin C, Zimmermann T, Berg T, et al. Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012. *Z Gastroenterol.* 2018;56(7):756-838.
6. Aghemo A, Masarone M, Montagnese S, et al. Assessing the impact of COVID-19 on the management of patients with liver diseases: a national survey by the Italian association for the study of the Liver. *Dig Liver Dis.* 2020;52(9):937-941.
7. German Federal Ministry of Health. [COVID-19, Current Vaccination Status]. <https://impfdashboard.de/>. Published 2021. Updated 2 June 2021. Accessed 3 June 2021.
8. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet gastroenterology & hepatology commission. *Lancet Gastroenterol Hepatol.* 2019;4(2):135-184.
9. Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. *Lancet.* 2021;399(10319):61-116.
10. Tergast TL, Kordecki N, Ohlendorf V, et al. Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure. *Z Gastroenterol.* 2021. doi:10.1055/a-1649-8931
11. Poethko-Muller C, Zimmermann R, Hamouda O, et al. Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for adults (DEGS1). *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.* 2013;56(5-6):707-715.
12. Robert Koch Institute. *SurvStat.* <http://www3.rki.de/SurvStat>. Published 2013. Updated 2013. Accessed 8/28/2013, 2013.
13. Wolfram I, Petroff D, Bätz O, et al. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. *J Hepatol.* 2015;62(6):1256-1264.
14. Bruggmann P, Berg T, Ovrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. *J Viral Hepat.* 2014;21(Suppl 1):5-33.
15. Destatis (Federal Statistics Office). *Foreigners: Germany, Years, Sex, Changes in the Register (Federal Level): Net immigration from Abroad.* 2019. Destatis (Federal Statistics Office); 2020.
16. Mattlinger C, Thumfart JO, Heinen W, et al. Hepatitis C virus seroprevalence and dependency on country of origin of refugees in Rhineland-Palatinate, Germany in 2015. *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.* 2018;61(11):1472-1480.
17. Jablonka A, Solbach P, Wöbse M, et al. Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. *Eur J Gastro Hepatol.* 2017;29(8):939-945.
18. Robert Koch Institute. Database Query with Estimates of the Incidence, Prevalence and Survival of Cancer in Germany based on the Epidemiological State Cancer Registry Data. In: Center for Cancer Registry Data in the Robert Koch Institute, ed. Federal Statistics Office 2019.
19. Robert Koch Institute. *Krebs in Deutschland für 2013/2014; 2017.*
20. Gredner T, Behrens G, Stock C, Brenner H, Mons U. Cancers due to infection and selected environmental factors. *Dtsch Arztebl Int.* 2018;115(35-36):586-593.
21. Kirstein MM, Schweitzer N, Winter T, et al. Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: experience from a German referral center. *J Gastroenterol Hepatol.* 2017;32(10):1730-1738.
22. Zimmermann R, Kulper-Schiek W, Steffen G, et al. How to assess the elimination of viral hepatitis B, C, and D in Germany? outcomes of an interdisciplinary workshop. *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.* 2021;64(1):77-90.
23. Gamkrelidze I, Pawlotsky J-M, Lazarus JV, et al. Progress towards hepatitis C virus elimination in high-income countries: an updated analysis. *Liver Int.* 2021;41(3):456-463.
24. Hüppe D, Niederau C, Serfert Y, Hartmann H, Wedemeyer H. Problems in treating patients with chronic HCV infection due to the COVID-19 pandemic and during the lockdown phase in Germany. *Z Gastroenterol.* 2020;58(12):1182-1185.
25. Hoebel J, Richter M, Lampert T. Social status and participation in health checks in men and women in Germany: results from the German Health Update (GEDA), 2009 and 2010. *Dtsch Arztebl Int.* 2013;110(41):679-685.
26. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C screening among adults - United States, 2020. *MMWR Recomm Rep.* 2020;69(2):1-17.
27. Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens. *Clin Gastroenterol Hepatol.* 2019;17(5):930-939 e939.
28. Waked I, Esmat G, Elsharkawy A, et al. Screening and treatment program to eliminate hepatitis C in Egypt. *N Engl J Med.* 2020;382(12):1166-1174.
29. Zimmermann R, Seidel J, Simeonova Y, Schmidt D, Dudareva-Vizule S, Bremer V. *Hepatitis C im Jahr 2016.* Robert Koch-Institut, Infektionsepidemiologie; 2017.
30. Bremer V, Cai W, Gassowski M, et al. *Drogen und chronische Infektionskrankheiten in Deutschland - DRUCK-Studie.* Robert Koch-Institut; 2016.
31. Sandmann L, Deppe J, Beier C, et al. Reaching the unreachable: strategies for HCV eradication in patients with refractory opioid addiction—a real-world experience. *Open Forum Infect Dis.* 2021;8(8):ofab325.
32. Dichtl A, Steffen G, Zimmermann R. *Bericht des DRUCK 2.0 Vorbereitungstreffens, 30 - 31. Oktober 2018.* Robert Koch-Institut; 2019:1-48.
33. Hollande C, Parlati L, Pol S. Micro-elimination of hepatitis C virus. *Liver Int.* 2020;40(Suppl 1):67-71.
34. Prestileo T, Marco VD, Dino O, et al. LBP-11-Is it possible to successfully link migrants from low-income countries to HBV, HCV, and HIV services upon arrival in the European Union? *J Hepatol.* 2019;70(1):e146.
35. European Centre for Disease Prevention and Control. *Technical protocol for hepatitis C prevalence surveys in the general population.* ECDC; 2020.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Tergast TL, Blach S, Tacke F, et al. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. *J Viral Hepat.* 2022;00:1-7. doi:[10.1111/jvh.13680](https://doi.org/10.1111/jvh.13680)